Efficacy of Mirabegron Compared with Tolterodine, Placebo, and Different Doses of Mirabegron on OAB Patient Evaluated in 4 Weeks Period: A Meta-Analysis
Asian Journal of Research and Reports in Urology,
Introduction: Mirabegron is one of the therapeutic options in overactive bladder where its efficacy and safety are better than antimuscarinics in several existing studies. Tolerability, treatment duration, and cost are often the deciding points for patient adherence and compliance in taking treatments. Many patients and doctors expect fast and visible results with relatively short treatments duration. This meta-analysis study describes and compares the efficacy of mirabegron compared with antimuscarinic, placebo or different doses of mirabegron over 4 weeks’ treatment range.
Methods: A literature search was performed using the Cochrane Library, Pubmed, and 5 other journal database. The literature reviewed included randomized and nonrandomized prospective and clinical trial studies. Mean difference (MD) was used to assess micturition frequency, incontinence episode, mean volume voided, nocturia episodes, urgency episodes, urgency incontinence episodes, and level of urgency of patients recorded within 4 weeks treatment duration. We used the Cochrane Collaboration’s Review Manager 5.4.1 software for statistical analysis
Results: Six publications that met eligibility criteria was included in this study. Meta-analysis of extractable data showed that Mirabegron was found significantly more efficacious than placebo for majority of efficacy endpoints recorded within 4 weeks’ treatment duration. In contrast, the comparison of mirabegron with tolterodine 4 mg showed no significant difference in outcome across all seven assessment criteria. On the other hand, mirabegron was also found to be more efficacious when administered in higher doses compared to lower doses at the majority efficacy endpoint
Conclusion: Withtin 4-week treatment duration, Mirabegron can provide significant results compared to placebo. However, the results are still not much different from tolterodine. Higher doses of mirabegron also provide a better result when compared with lower doses. The lowest dose with statistically significant results compared to placebo was obtained from mirabegron 25 mg.
- overactive bladder
How to Cite
Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowski R, et al. A comprehensive review of overactive bladder pathophysiology: On the way to tailored treatment (Figure presented.). Eur Urol. 2019;75(6):988–1000.
Eapen RS, Radomski SB. Review of the epidemiology of overactive bladder. Res Reports Urol. 2016;8:71–6.
Chuang YC, Liu SP, Lee KS, Liao L, Wang J, Yoo TK, et al. Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study. LUTS Low Urin Tract Symptoms. 2019;11(1):48–55.
Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (Non-Neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(6 SUPPL.):558.
Wang CL, Wu CH, Liu CM, Shen CJ, Lin KL, Long CY. Clinical and urodynamic effects of tolterodine in women with an overactive bladder. Taiwan J Obstet Gynecol. 2013;52(3):381–4.
Shen YC, Wang HJ, Chuang YC. Efficacy and persistence of low-doses mirabegron (25 mg) in patients with overactive bladder: Analysis in a real-world urological practice. Int Urol Nephrol. 2018;50(7):1219–26.
Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: A retrospective observational study in UK clinical practice. Eur Urol. 2017;72(3):389–99.
Sussman D, Yehoshua A, Kowalski J, Lee W, Kish J, Chaudhari S, et al. Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis. Int J Clin Pract. 2017;71(3–4):1–8.
Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: Results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–95.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372.
Willis-Gray MG, Dieter AA, Geller EJ. Evaluation and management of overactive bladder: Strategies for optimizing care. Res Reports Urol. 2016;8:113–22.
Yamaguchi O, Marui E, Igawa Y, Takeda M, Nishizawa O, Ikeda Y, et al. Efficacy and safety of the selective β3-adrenoceptor agonist mirabegron in japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled, doses-finding study. LUTS Low Urin Tract Symptoms. 2015;7(2):84–92.
Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, et al. Safety and efficacy of mirabegron: Analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo[Formula presented]. Eur Urol. 2020;77(1):119–28.
Cui Y, Zong H, Yang C, Yan H, Zhang Y. The efficacy and safety of mirabegron in treating OAB: A systematic review and meta-analysis of phase III trials. Int Urol Nephrol. 2014;46(1):275–84.
Wu T, Duan X, Cao CX, Peng C Du, Bu SY, Wang KJ. The role of mirabegron in overactive bladder: A systematic review and meta-analysis. Urol Int. 2014;93(3):326–37.
Sebastianelli A, Russo GI, Kaplan SA, McVary KT, Moncada I, Gravas S, et al. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine. Int J Urol. 2018;25(3): 196–205.
Abstract View: 36 times
PDF Download: 8 times